neuromuscular diseases
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: We searched PubMed, the Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi until published up to July 2024. We included randomized controlled trials (RCTs) and non-randomized studies comparing IV to NIV, or NIV to any forms of oxygen therapies, or NIV to any forms of oxygen therapies for acute respiratory failure in neuromuscular diseases.
Exclusion criteria
Exclusion criteria: We searched PubMed, the Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi until published up to July 2024. We included randomized controlled trials (RCTs) and non-randomized studies comparing IV to NIV, or NIV to any forms of oxygen therapies, or NIV to any forms of oxygen therapies for acute respiratory failure in neuromuscular diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mortality | — |
Secondary
| Measure | Time frame |
|---|---|
| Length of stay in the ICU, good neurological outcome rates, duration of ventilation, avoiding tracheotomy, pneumonia. | — |
Countries
Japan
Contacts
Touto Sangenjyaya Rehabilitation Hospital Department of Neurology